-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Englitazone net SGLT2 inhibitors belong to a new generation, in August 2014 by the US Food and Drug Administration Bureau ( the FDA ) approved after September 2017 approved the listing in mainland China.
Manage FDA diabetes
Unlike other oral drugs currently used to treat type II diabetes, Enge's first column is the net SGLT2 class of antidiabetic agents complete medsci.
Engel is the first column net SGLT2 class of antidiabetic drugs only complete medsci.
Previously, research published in the American Journal of Cardiovascular Medicine (JACC) showed that the diuretic effect of empagliflozin does not play a leading role in the physiological changes or clinical benefits of HFrEF patients .
The diuretic effect of empagliflozin does not play a leading role in the physiological changes or clinical benefits of HFrEF patients.
The health of all participants was assessed by the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS).
In general, regardless of the baseline KCCQ-CSS score, treatment with empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization [the scores were divided into <62.
Regardless of the baseline KCCQ-CSS score, treatment with empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization [the scores were divided into <62.
Empagliflozin improved KCCQ-CSS, total symptom score, and overall scores at 3 months, 8 months, and 12 months.
In addition, these benefits persist at 8 and 12 months, and are similar in other KCCQ areas.
In summary, in the entire baseline health status range, empagliflozin improved the risk of cardiovascular death or heart failure hospitalization in patients with HFrEF.
Enpagliflozin improved the risk of cardiovascular death or heart failure hospitalization in patients with HFrEF across the range of baseline health status.
references:
silverchair.
silverchair.
com/ehaa1007.
pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAArEwggKtBgkqhkiG9w0BBwagggKeMIICmgIBADCCApMGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMjLAuA7_Y-n9HzWQAAgEQgIICZP5OVd53f79IXvBY8Fb-LTJih60NGfgtM-e9Oy7enpMMbsupjZ2LBJ4OligzGviCQOn4QguUBIMZ0JWz6bUy6SZm7D2bEShYpBn2yCBhOfgGkhcmnf0s7dMKmC9Wb08LtjoOeGD9umaHNr7JMr0572sbLRkfJ2Vhv31N054VqtcXQk0aFk0HIFcvIZA0jVZuSq5IsJW8En1IBDUZhjL2kBugqqq3w_zmILB5f6s2fYksSsC_lWChaA0Wtcdh-1Nwsd-2ww9boahHEfRTpkBUbwxcgshFGqL5rO4pJwjH19I-fvovLNCCkGJh2jlA6LWIWTm6uuZNg11312C3R4jIwgBctpoo5RxjN1ufKCiDisLbXlgpCXDAY7BaeD7Lmsuh3h-acRBWTzcMLTDASlhRp2eXwizbOwbtNkSBvXvUrAKT5zQd2XEhoF1j5lgNkXeg_SvdIAv39ia_WcOlncJNiMw9G6qeS3War0M9lMZkjxGeyNQm6r90WnRWjxb9qFUL7-kwDiI0Lg4Ozv2L0yzX1beLT4VIPWoTKPUtMAZgvPAGUcalzDAbxxOU4FtM80EiwapXgxTtSo6Rw79FCEfJahOSRTV7Wc6L9dD2QhUydiVA7A1vq6tok7hPPm0DCCRcdg1FQzH1EuWNSnlhgTvM6m6etOLHIPtthppUOr9l-DTxsbk-A-9YY9OMPolV6dl5_ROPL8ABRKerZgp1rsV5KsUY2vz2Ch3Y0UeajUo58sBYppCdezCNW11VanCz0p9ptKj2918Qi1_GF2FojFLDbeLD2zuJfTBZ7oAhgH7ijzAudnulTA" target="_blank" rel="noopener">Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
Leave a message here
